Out of the Lab: Operationalizing Cell and Gene Therapy

Nicholas (Nico) Crudele
  • 0.0 (0)
  • ENTREPRENEURSHIP
  • UPDATED MONTHLY

tech transfer, process control, travel requirements, audits These silent operational breakdowns prevent life-saving cell and gene therapy treatments from ever reaching patients, and kill IP-backed companies. This show is for executives on the path to clinic, de-risking their clinical assets. Leverage insights hard-earned from countless years in the industry, ranging from the manufactuirng floor through to leadership. Transform operations from your biggest risk into your greatest asset. See, understand and prepare for the challenges ahead on your clinical journey.

  1. 6D AGO

    You Don't Know What You Don't Know: The Hidden Traps in Tech Transfer with François-Xavier Lacasse

    Why does a process that works perfectly in a university lab suddenly fail when it hits a manufacturing facility? In this episode, we sit down with François-Xavier (FX) Lacasse, a 28-year industry veteran, to unpack the notorious friction of tech transfer. We dive into the fundamental language barrier between academia ("research for research") and industry ("research for development"), and why strict GMP/GLP compliance is such a difficult bridge to cross. FX shares some brilliant analogies to explain the reality of scaling up like why changing the pan you’ve cooked a recipe in for 15 years suddenly ruins the dish, or how failing to document a seemingly obvious detail (like the exact temperature of the water) leads to massive reproducibility failures in biotech with a much higher cost than a burnt omelet. Ultimately, it comes down to a simple truth: you don't know what you don't know. In this episode, we cover: - Understanding the physical realities of scaling from an Eppendorf tube to a bioreactor. - The danger of tacit knowledge and unwritten steps in Standard Operating Procedures. - Why documentation is the ultimate crux of successful tech transfer. - How early-stage oversights compound into massive costs during clinical trials.Show Notes: [00:00:22] – Introduction: FX’s background and 28 years of experience in pharmaceutical development. [00:01:26] – The Language Barrier: Understanding the massive gap between "Research for Research" (academia) and "Research for Development" (industry). [00:02:27] – Why you must involve Contract Development and Manufacturing Organizations (CDMOs) as early as possible to anticipate operational pitfalls. [00:04:21] – The Water Temperature Dilemma: How unwritten, tacit knowledge ruins reproducibility when handing off a procedure to another operator. [00:07:35] – Why comprehensive documentation is the absolute "crux of the matter" in tech transfer. [00:12:42] – The massive financial impact of failing to document operational details before hitting multi-million dollar clinical trials. [00:18:59] – The "Cooking Pan" Analogy: Why scaling up from an Eppendorf tube to a bioreactor breaks your process due to heat and mass transfer changes. [00:20:10] – "You don't know what you don't know" – Uncovering the hidden traps in early-stage process development. Connect with us on LinkedIn: Nicholas Crudele (host): François-Xavier (FX) Lacasse (guest):learn how Method Made addresses documentation challenges for tech transfer:

    21 min

  2. FEB 21

    Decentralizing the Cure: The Road to Community-Based CAR-T

    In this episode, host Nico sits down with repeat guest Lee Buckler to tackle the "80/20" problem in cell and gene therapy: the fact that while 80% of patients are treated in community settings, CAR-T therapies are currently stuck in high-level academic centers. We explore the history of patient access from the stem cell transplant model to the lessons learned from Dendreon’s Provenge and map out the infrastructure needed to bring these cures to the local level. From the "10-mile rule" of patient attrition to the massive financial hurdles of carrying multi-million dollar therapies on a hospital’s books, this conversation digs into the operational reality of scaling life-saving science Key Discussion Points The 10-Mile Rule: Why every 10 miles of distance from a treatment center results in a 6.2% drop in the likelihood of a patient receiving CAR-T. Infrastructure vs. Business Hurdles: Analyzing why the $500,000 to $3 million upfront cost of therapy creates massive cash-flow barriers for community hospitals.Decentralizing the "Vein-to-Vein" Process: How Blood Centers of America (BCA) and FACT are establishing new standards for local apheresis and infusion. Safety and Remote Monitoring: How wearable tech and reduced FDA REMS requirements are allowing patients to recover at home sooner. The Future of Cost: A look at how non-profit models and 5-year ROI data are shifting the payer landscape.Show Notes 00:21 – The dual history of cell therapy: Stem cell transplants vs. Provenge. 05:43 – The community access gap: Why CAR-T sales have plateaued at 20%. 11:48 – Expanding into autoimmune: Why local delivery is no longer optional. 19:30 – Logistics and Cryopreservation: Building a national infrastructure. 34:33 – Financial bottlenecks and the reality of reimbursement. 51:41 – Advancements in remote monitoring and patient safety. 58:48 – Insurance, ROI, and the rise of generic models.

    1h 4m

  3. FEB 15

    Tech Transfer Trauma: The High Cost of Going Back to the Bench

    In the current investment landscape, the "cool science" era of Cell and Gene Therapy is over. Investors have moved from unbridled optimism to rigorous risk management, yet many IP-backed companies still treat manufacturing as an afterthought, a strategic error that kills margins and delays clinics. In this episode, Nico sits down with Silvio Tiziani, CEO of CCRM Australia, to dissect the "Manufacturability Gap": the critical friction point where regulatory complexity and documentation failures amplify costs. We discuss the business case for early operational rigor, including: The Financial Reality of Rework: Why failing to consider GMP requirements during R&D leads to the ultimate nightmare scenario: returning to the lab bench for total process redesign. The "Widget" Investment Thesis: Silvio explains why the Australian market favors modular, versatile "widgets" over the "single magic box" approach and why this versatility makes for a more attractive, de-risked financial asset. From Founder to Executive: The necessary mindset shift from academic curiosity to commercial competence, and why your pitch must pivot from "technical novelty" to "risk management" to resonate with today's circumspect investors.Join us to learn how to transform operations from your biggest liability into your greatest asset.

    26 min

  4. JAN 28

    The 80/20 Gap: Why Life-Saving Cures Are Stalling (Teaser)

    "The number one hashtag on everybody's lips is patient accessibility." In this pre-episode teaser, we dive into the sobering reality of the "80/20 Gap" in cell and gene therapy. While the industry has celebrated the arrival of highly curative CAR T-cell therapies, a massive logistical wall has been hit. Lee Buckler joins us to unpack why sales of these "wonderful widgets" are flattening just as they should be scaling. We discuss: The Geographic Divide: Why 80% of cancer patients treated in community healthcare settings are effectively locked out of therapies available only at advanced medical centers (AMCs). The flattening of CAR T: A look at why adoption has stalled at 20%—the exact percentage of patients with easy access to city-center hubs. Beyond the Science: Why the "attractive option" of a cure disappears when a patient faces a five-hour drive, three weeks of city living costs, and a lack of local support systems. The Path to Decentralization: How "boxed-in" physical systems and operational engineering are working to bring manufacturing and processing closer to the patient’s home. If we don't move the therapy to the patient, we leave 80% of the population behind. Join us as we explore the infrastructure and "contractual engineering" required to break CAR-T out of the ivory tower and into the community. Stay tuned for the full episode.

    10 min

  5. JAN 28

    The Scalability Trap: Why Flexibility is the Future of CGT Manufacturing

    "The tradition is we start with open manual processes: flasks and clean rooms, thinking we can automate and scale and worry about cost of goods later." In this episode, Lee Buckler (Cell Therapy Group) and Nicholas Crudele (Method Made) explore why the "science project" phase of Cell & Gene Therapy often leads to a tech-transfer dead end. But the answer isn’t necessarily locking your process into a rigid, all-in-one "black box" early on. Lee argues for a different path: the "daisy chain" of technologies. Instead of one box that does everything (and limits innovation), the future of the lab is a series of specialized "widgets" digitally connected to ensure compliance without sacrificing flexibility. We discuss how these widget technologies act as the digital glue for this daisy chain, capturing manual breakthroughs today and turning them into the automated, scalable protocols of tomorrow. Highlights: Why the "worry about it later" mentality around manufacturing is a company killer. The "One Box" vs. "Daisy Chain" debate: Why flexibility wins in R&D.

    53 min

  6. 12/13/2025

    Tech Transfer 101: Engineering Out the "Secret Sauce"

    If your process relies on the "golden hands" of a specific scientist, you don't have a product, you have a research project. Nicholas Crudele and Arnaud Deladeriere discuss the critical leap from academic science to GMP manufacturing in cell and gene therapy. We cover: What is CMC? (A primer for founders) . Why the "Product is the Process" mindset fails in cell therapy. How to use "process parameters" as dials to control patient variability. Why you should use GMP materials as early as possible.

    46 min

  7. 12/13/2025

    Demystifying CMC: Tech Transfer, Investor Pressures, and the "Time vs. Money" Trap

    What exactly is CMC, and why is it the backbone of pharmaceutical quality? In this episode, Nicholas sits down with Jeffrey Seres to break down the complexities of Chemistry, Manufacturing, and Controls for early-stage founder-scientists. From the friction between aggressive VC timelines and operational realities to the future of documentation, we cover the critical gaps in moving from R&D to commercial manufacturing. Topics covered: Defining CMC: The control and oversight governing manufacturing quality. The Strategy Gap: Why rushed timelines destroy CMC strategy and how to mitigate "Time vs. Money" arguments with investors. Board Composition: Why startups need operational expertise, not just bankers and academics, on their boards. The Future of Docs: Why putting paper on an iPad isn't true digitization—and why full process automation is the real goal.

    26 min

  8. 11/12/2025

    The Light in the Lab: Why a Single Missed Detail Can Kill Your Tech Transfer

    Are you an R&D-focused founder who thinks of manufacturing as a problem for "later"? This episode is a critical wake-up call. CMC expert and Managing Director David Bruehlmann joins the podcast to explain why a staggering number of promising therapies fail due to CMC issues and how treating "details" as an afterthought can lead to catastrophic failures. We dive into the story of a real-world tech transfer that failed, not because of the equipment, but because of a single, un-documented variable: the light exposure in the lab. This conversation is essential listening for any scientist, engineer, or founder preparing to scale their process. In this episode, you will learn: What CMC Strategy Is: Why it's not an "afterthought" but a strategic asset that must be built from day one. The "Quality by Design" Mindset: How to work backward from the patient to define your critical process parameters and control strategy. How to Choose a CDMO: Why the right partner is about cultural fit, size, and experience—not just the lowest cost. Why CGT is Harder: The fundamental difference between biologics ("the process is the product") and cell therapy ("the cell is the product"). The R&D vs. Engineering Mindset: The critical (and necessary) culture clash between scientists focused on results and engineers focused on robustness. If you would like to suggest future episode topics and/or guests, get in touch on LinkedIn

    40 min
See All (20)

About

tech transfer, process control, travel requirements, audits These silent operational breakdowns prevent life-saving cell and gene therapy treatments from ever reaching patients, and kill IP-backed companies. This show is for executives on the path to clinic, de-risking their clinical assets. Leverage insights hard-earned from countless years in the industry, ranging from the manufactuirng floor through to leadership. Transform operations from your biggest risk into your greatest asset. See, understand and prepare for the challenges ahead on your clinical journey.

Information